#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6 .
1-1	0-1	6	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=What do the Clinical Data Teach Us ?
2-1	4-8	What	_	_	_	_
2-2	9-11	do	_	_	_	_
2-3	12-15	the	abstract[2]	new[2]	_	_
2-4	16-24	Clinical	abstract[2]	new[2]	_	_
2-5	25-29	Data	abstract[2]	new[2]	_	_
2-6	30-35	Teach	person[3]	acc[3]	_	_
2-7	36-38	Us	person[3]	acc[3]	_	_
2-8	39-40	?	_	_	_	_

#Text=As discussed above , the great majority of the radiobiological investigations have been done with very radioresistant and hyper-radiosensitive cells .
3-1	41-43	As	_	_	_	_
3-2	44-53	discussed	_	_	_	_
3-3	54-59	above	_	_	_	_
3-4	60-61	,	_	_	_	_
3-5	62-65	the	event[4]	new[4]	_	_
3-6	66-71	great	event[4]	new[4]	_	_
3-7	72-80	majority	event[4]	new[4]	_	_
3-8	81-83	of	event[4]	new[4]	_	_
3-9	84-87	the	event[4]|event[5]	new[4]|new[5]	_	_
3-10	88-103	radiobiological	event[4]|event[5]	new[4]|new[5]	_	_
3-11	104-118	investigations	event[4]|event[5]	new[4]|new[5]	_	_
3-12	119-123	have	_	_	_	_
3-13	124-128	been	_	_	_	_
3-14	129-133	done	_	_	_	_
3-15	134-138	with	_	_	_	_
3-16	139-143	very	object[6]	new[6]	coref	10-3[51_6]
3-17	144-158	radioresistant	object[6]	new[6]	_	_
3-18	159-162	and	object[6]	new[6]	_	_
3-19	163-183	hyper-radiosensitive	object[6]	new[6]	_	_
3-20	184-189	cells	object[6]	new[6]	_	_
3-21	190-191	.	_	_	_	_

#Text=However , the hyper-radiosensitive and hyper-radioresistant cellular models are not representative of the clinical reality .
4-1	192-199	However	_	_	_	_
4-2	200-201	,	_	_	_	_
4-3	202-205	the	abstract[8]	new[8]	coref	17-9[114_8]
4-4	206-226	hyper-radiosensitive	abstract[8]	new[8]	_	_
4-5	227-230	and	abstract[8]	new[8]	_	_
4-6	231-251	hyper-radioresistant	abstract[8]	new[8]	_	_
4-7	252-260	cellular	abstract|abstract[8]	new|new[8]	_	_
4-8	261-267	models	abstract[8]	new[8]	_	_
4-9	268-271	are	_	_	_	_
4-10	272-275	not	_	_	_	_
4-11	276-290	representative	_	_	_	_
4-12	291-293	of	_	_	_	_
4-13	294-297	the	abstract[9]	new[9]	_	_
4-14	298-306	clinical	abstract[9]	new[9]	_	_
4-15	307-314	reality	abstract[9]	new[9]	_	_
4-16	315-316	.	_	_	_	_

#Text=For example , there is no known human genetic syndromes caused by mutations of Ku or DNA-PKcs proteins , the major NHEJ actors .
5-1	317-320	For	_	_	_	_
5-2	321-328	example	_	_	_	_
5-3	329-330	,	_	_	_	_
5-4	331-336	there	_	_	_	_
5-5	337-339	is	_	_	_	_
5-6	340-342	no	abstract[10]	new[10]	coref	11-12[58_10]
5-7	343-348	known	abstract[10]	new[10]	_	_
5-8	349-354	human	abstract[10]	new[10]	_	_
5-9	355-362	genetic	abstract[10]	new[10]	_	_
5-10	363-372	syndromes	abstract[10]	new[10]	_	_
5-11	373-379	caused	_	_	_	_
5-12	380-382	by	_	_	_	_
5-13	383-392	mutations	abstract[11]	new[11]	_	_
5-14	393-395	of	abstract[11]	new[11]	_	_
5-15	396-398	Ku	abstract[11]|abstract	new[11]|new	_	_
5-16	399-401	or	abstract[11]	new[11]	_	_
5-17	402-410	DNA-PKcs	abstract[11]|abstract|substance[14]	new[11]|new|new[14]	coref|coref|coref|coref	11-5[56_14]|17-29[120_0]|11-5[56_14]|17-29[120_0]
5-18	411-419	proteins	abstract[11]|substance[14]	new[11]|new[14]	_	_
5-19	420-421	,	abstract[11]	new[11]	_	_
5-20	422-425	the	abstract[11]|person[16]	new[11]|new[16]	_	_
5-21	426-431	major	abstract[11]|person[16]	new[11]|new[16]	_	_
5-22	432-436	NHEJ	abstract[11]|abstract|person[16]	new[11]|new|new[16]	coref	6-9
5-23	437-443	actors	abstract[11]|person[16]	new[11]|new[16]	_	_
5-24	444-445	.	_	_	_	_

#Text=The only human case of gross defect in NHEJ function to non-viability was caused by mutations of DNA ligase IV ( LIG4 ) .
6-1	446-449	The	abstract[17]	new[17]	_	_
6-2	450-454	only	abstract[17]	new[17]	_	_
6-3	455-460	human	abstract[17]	new[17]	_	_
6-4	461-465	case	abstract[17]	new[17]	_	_
6-5	466-468	of	abstract[17]	new[17]	_	_
6-6	469-474	gross	abstract[17]|abstract[18]	new[17]|new[18]	coref	14-9[84_18]
6-7	475-481	defect	abstract[17]|abstract[18]	new[17]|new[18]	_	_
6-8	482-484	in	abstract[17]|abstract[18]	new[17]|new[18]	_	_
6-9	485-489	NHEJ	abstract[17]|abstract[18]|organization|abstract[20]	new[17]|new[18]|giv|new[20]	coref|coref	17-32|17-32
6-10	490-498	function	abstract[17]|abstract[18]|abstract[20]	new[17]|new[18]|new[20]	_	_
6-11	499-501	to	abstract[17]|abstract[18]|abstract[20]	new[17]|new[18]|new[20]	_	_
6-12	502-515	non-viability	abstract[17]|abstract[18]|abstract[20]	new[17]|new[18]|new[20]	_	_
6-13	516-519	was	_	_	_	_
6-14	520-526	caused	_	_	_	_
6-15	527-529	by	_	_	_	_
6-16	530-539	mutations	abstract[21]	new[21]	coref	7-24[33_21]
6-17	540-542	of	abstract[21]	new[21]	_	_
6-18	543-546	DNA	abstract[21]|abstract	new[21]|new	_	_
6-19	547-553	ligase	_	_	_	_
6-20	554-556	IV	abstract[23]	new[23]	_	_
6-21	557-558	(	abstract[23]	new[23]	_	_
6-22	559-563	LIG4	abstract[23]|substance	new[23]|new	coref	15-17
6-23	564-565	)	abstract[23]	new[23]	_	_
6-24	566-567	.	_	_	_	_

#Text=The majority of cases of fatal post-radiotherapy events were encountered after whole-body irradiation of children with ataxia telangiectasia ( AT ) caused by homozygous ATM mutations during their anti-leukemia or lymphoma treatment .
7-1	568-571	The	abstract[25]	new[25]	_	_
7-2	572-580	majority	abstract[25]	new[25]	_	_
7-3	581-583	of	abstract[25]	new[25]	_	_
7-4	584-589	cases	abstract[25]	new[25]	_	_
7-5	590-592	of	abstract[25]	new[25]	_	_
7-6	593-598	fatal	abstract[25]|abstract[27]	new[25]|new[27]	_	_
7-7	599-616	post-radiotherapy	abstract[25]|organization|abstract[27]	new[25]|new|new[27]	_	_
7-8	617-623	events	abstract[25]|abstract[27]	new[25]|new[27]	_	_
7-9	624-628	were	_	_	_	_
7-10	629-640	encountered	_	_	_	_
7-11	641-646	after	_	_	_	_
7-12	647-657	whole-body	abstract[28]	new[28]	coref	21-18[0_28]
7-13	658-669	irradiation	abstract[28]	new[28]	_	_
7-14	670-672	of	abstract[28]	new[28]	_	_
7-15	673-681	children	abstract[28]|person	new[28]|new	ana	7-28
7-16	682-686	with	abstract[28]	new[28]	_	_
7-17	687-693	ataxia	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-18	694-708	telangiectasia	abstract[28]|abstract[30]	new[28]|new[30]	_	_
7-19	709-710	(	_	_	_	_
7-20	711-713	AT	_	_	_	_
7-21	714-715	)	_	_	_	_
7-22	716-722	caused	_	_	_	_
7-23	723-725	by	_	_	_	_
7-24	726-736	homozygous	person|abstract[33]	new|giv[33]	coref|coref	11-7[57_33]|11-7[57_33]
7-25	737-740	ATM	object|abstract[33]	new|giv[33]	coref	15-20
7-26	741-750	mutations	abstract[33]	giv[33]	_	_
7-27	751-757	during	abstract[33]	giv[33]	_	_
7-28	758-763	their	abstract[33]|person|abstract[35]|event[37]	giv[33]|giv|new[35]|new[37]	_	_
7-29	764-777	anti-leukemia	abstract[33]|abstract[35]|event[37]	giv[33]|new[35]|new[37]	_	_
7-30	778-780	or	abstract[33]|event[37]	giv[33]|new[37]	_	_
7-31	781-789	lymphoma	abstract[33]|abstract|event[37]	giv[33]|new|new[37]	_	_
7-32	790-799	treatment	abstract[33]|event[37]	giv[33]|new[37]	_	_
7-33	800-801	.	_	_	_	_

#Text=It is important to note that AT frequency is of about 1/100,000 .
8-1	802-804	It	abstract	new	cata	8-1[0_39]
8-2	805-807	is	_	_	_	_
8-3	808-817	important	_	_	_	_
8-4	818-820	to	abstract[39]	new[39]	_	_
8-5	821-825	note	abstract[39]	new[39]	_	_
8-6	826-830	that	abstract[39]	new[39]	_	_
8-7	831-833	AT	abstract[39]	new[39]	_	_
8-8	834-843	frequency	abstract[39]|abstract	new[39]|new	_	_
8-9	844-846	is	abstract[39]	new[39]	_	_
8-10	847-849	of	abstract[39]	new[39]	_	_
8-11	850-855	about	abstract[39]|quantity[41]	new[39]|new[41]	_	_
8-12	856-865	1/100,000	abstract[39]|quantity[41]	new[39]|new[41]	_	_
8-13	866-867	.	_	_	_	_

#Text=By contrast , about 5 % – 20 % cancer of patients treated by radiotherapy exhibit post-radiotherapy tissue reactions that can be considered as moderate radiosensitivity .
9-1	868-870	By	_	_	_	_
9-2	871-879	contrast	abstract	new	coref	25-2
9-3	880-881	,	_	_	_	_
9-4	882-887	about	quantity[43]	new[43]	_	_
9-5	888-889	5	quantity[43]	new[43]	_	_
9-6	890-891	%	quantity[43]	new[43]	_	_
9-7	892-893	–	quantity[43]	new[43]	_	_
9-8	894-896	20	quantity[43]|quantity[44]	new[43]|new[44]	_	_
9-9	897-898	%	quantity[43]|quantity[44]	new[43]|new[44]	_	_
9-10	899-905	cancer	abstract[45]	new[45]	coref	12-12[0_45]
9-11	906-908	of	abstract[45]	new[45]	_	_
9-12	909-917	patients	abstract[45]|person	new[45]|new	_	_
9-13	918-925	treated	_	_	_	_
9-14	926-928	by	_	_	_	_
9-15	929-941	radiotherapy	abstract	new	_	_
9-16	942-949	exhibit	_	_	_	_
9-17	950-967	post-radiotherapy	abstract[49]	new[49]	ana	11-3[55_49]
9-18	968-974	tissue	object|abstract[49]	new|new[49]	_	_
9-19	975-984	reactions	abstract[49]	new[49]	_	_
9-20	985-989	that	_	_	_	_
9-21	990-993	can	_	_	_	_
9-22	994-996	be	_	_	_	_
9-23	997-1007	considered	_	_	_	_
9-24	1008-1010	as	_	_	_	_
9-25	1011-1019	moderate	_	_	_	_
9-26	1020-1036	radiosensitivity	_	_	_	_
9-27	1037-1038	.	_	_	_	_

#Text=Surprisingly , no or very few rodent cells with moderate radiosensitivity have been the subject of a published radiobiological characterization .
10-1	1039-1051	Surprisingly	_	_	_	_
10-2	1052-1053	,	_	_	_	_
10-3	1054-1056	no	object[51]	giv[51]	coref	10-14[53_51]
10-4	1057-1059	or	object[51]	giv[51]	_	_
10-5	1060-1064	very	object[51]	giv[51]	_	_
10-6	1065-1068	few	object[51]	giv[51]	_	_
10-7	1069-1075	rodent	animal|object[51]	new|giv[51]	_	_
10-8	1076-1081	cells	object[51]	giv[51]	_	_
10-9	1082-1086	with	object[51]	giv[51]	_	_
10-10	1087-1095	moderate	object[51]|abstract[52]	giv[51]|new[52]	coref	12-23[66_52]
10-11	1096-1112	radiosensitivity	object[51]|abstract[52]	giv[51]|new[52]	_	_
10-12	1113-1117	have	_	_	_	_
10-13	1118-1122	been	_	_	_	_
10-14	1123-1126	the	object[53]	giv[53]	coref	15-21[94_53]
10-15	1127-1134	subject	object[53]	giv[53]	_	_
10-16	1135-1137	of	object[53]	giv[53]	_	_
10-17	1138-1139	a	object[53]|abstract[54]	giv[53]|new[54]	_	_
10-18	1140-1149	published	object[53]|abstract[54]	giv[53]|new[54]	_	_
10-19	1150-1165	radiobiological	object[53]|abstract[54]	giv[53]|new[54]	_	_
10-20	1166-1182	characterization	object[53]|abstract[54]	giv[53]|new[54]	_	_
10-21	1183-1184	.	_	_	_	_

#Text=Interestingly , some of the proteins whose mutations are responsible for these syndromes were cited as components of the different variants of A-NHEJ ( see Section 4 ) .
11-1	1185-1198	Interestingly	_	_	_	_
11-2	1199-1200	,	_	_	_	_
11-3	1201-1205	some	abstract[55]	giv[55]	_	_
11-4	1206-1208	of	abstract[55]	giv[55]	_	_
11-5	1209-1212	the	abstract[55]|substance[56]	giv[55]|giv[56]	coref	13-13[77_56]
11-6	1213-1221	proteins	abstract[55]|substance[56]	giv[55]|giv[56]	_	_
11-7	1222-1227	whose	abstract[57]	giv[57]	_	_
11-8	1228-1237	mutations	abstract[57]	giv[57]	_	_
11-9	1238-1241	are	_	_	_	_
11-10	1242-1253	responsible	_	_	_	_
11-11	1254-1257	for	_	_	_	_
11-12	1258-1263	these	abstract[58]	giv[58]	coref	12-4[62_58]
11-13	1264-1273	syndromes	abstract[58]	giv[58]	_	_
11-14	1274-1278	were	_	_	_	_
11-15	1279-1284	cited	_	_	_	_
11-16	1285-1287	as	_	_	_	_
11-17	1288-1298	components	_	_	_	_
11-18	1299-1301	of	_	_	_	_
11-19	1302-1305	the	abstract[59]	new[59]	_	_
11-20	1306-1315	different	abstract[59]	new[59]	_	_
11-21	1316-1324	variants	abstract[59]	new[59]	_	_
11-22	1325-1327	of	abstract[59]	new[59]	_	_
11-23	1328-1334	A-NHEJ	abstract[59]|abstract	new[59]|new	_	_
11-24	1335-1336	(	_	_	_	_
11-25	1337-1340	see	_	_	_	_
11-26	1341-1348	Section	abstract[61]	new[61]	_	_
11-27	1349-1350	4	abstract[61]	new[61]	_	_
11-28	1351-1352	)	_	_	_	_
11-29	1353-1354	.	_	_	_	_

#Text=In addition , some genetic syndromes , associated or not with cancer proneness , different from the precited ones , also show a moderate radiosensitivity : this is notably the case of neurofibromatosis , Huntington ’s chorea , and tuberous sclerosis syndromes .
12-1	1355-1357	In	_	_	_	_
12-2	1358-1366	addition	_	_	_	_
12-3	1367-1368	,	_	_	_	_
12-4	1369-1373	some	abstract[62]	giv[62]	coref	12-40[73_62]
12-5	1374-1381	genetic	abstract[62]	giv[62]	_	_
12-6	1382-1391	syndromes	abstract[62]	giv[62]	_	_
12-7	1392-1393	,	_	_	_	_
12-8	1394-1404	associated	_	_	_	_
12-9	1405-1407	or	_	_	_	_
12-10	1408-1411	not	_	_	_	_
12-11	1412-1416	with	_	_	_	_
12-12	1417-1423	cancer	abstract|abstract[64]	giv|new[64]	coref|coref|coref|coref	25-20|25-20[172_64]|25-20|25-20[172_64]
12-13	1424-1433	proneness	abstract[64]	new[64]	_	_
12-14	1434-1435	,	_	_	_	_
12-15	1436-1445	different	_	_	_	_
12-16	1446-1450	from	_	_	_	_
12-17	1451-1454	the	abstract[65]	new[65]	_	_
12-18	1455-1463	precited	abstract[65]	new[65]	_	_
12-19	1464-1468	ones	abstract[65]	new[65]	_	_
12-20	1469-1470	,	_	_	_	_
12-21	1471-1475	also	_	_	_	_
12-22	1476-1480	show	_	_	_	_
12-23	1481-1482	a	abstract[66]	giv[66]	ana	12-27[0_66]
12-24	1483-1491	moderate	abstract[66]	giv[66]	_	_
12-25	1492-1508	radiosensitivity	abstract[66]	giv[66]	_	_
12-26	1509-1510	:	_	_	_	_
12-27	1511-1515	this	abstract	giv	coref	12-29[68_0]
12-28	1516-1518	is	_	_	_	_
12-29	1519-1526	notably	abstract[68]	giv[68]	ana	13-1[0_68]
12-30	1527-1530	the	abstract[68]	giv[68]	_	_
12-31	1531-1535	case	abstract[68]	giv[68]	_	_
12-32	1536-1538	of	abstract[68]	giv[68]	_	_
12-33	1539-1556	neurofibromatosis	abstract[68]|abstract	giv[68]|new	_	_
12-34	1557-1558	,	abstract[68]	giv[68]	_	_
12-35	1559-1569	Huntington	abstract[68]|place[70]|abstract[71]	giv[68]|new[70]|new[71]	_	_
12-36	1570-1572	’s	abstract[68]|place[70]|abstract[71]	giv[68]|new[70]|new[71]	_	_
12-37	1573-1579	chorea	abstract[68]|abstract[71]	giv[68]|new[71]	_	_
12-38	1580-1581	,	abstract[68]	giv[68]	_	_
12-39	1582-1585	and	abstract[68]	giv[68]	_	_
12-40	1586-1594	tuberous	abstract[68]|abstract[73]	giv[68]|giv[73]	coref	13-6[75_73]
12-41	1595-1604	sclerosis	abstract[68]|abstract|abstract[73]	giv[68]|new|giv[73]	_	_
12-42	1605-1614	syndromes	abstract[68]|abstract[73]	giv[68]|giv[73]	_	_
12-43	1615-1616	.	_	_	_	_

#Text=It must be stressed that these syndromes are caused by mutations of cytoplasmic proteins , which may contradict the historical hypothesis that nucleus is the most radiosensitive part of the cell ( see the Introduction ) .
13-1	1617-1619	It	abstract	giv	coref	14-18[88_0]
13-2	1620-1624	must	_	_	_	_
13-3	1625-1627	be	_	_	_	_
13-4	1628-1636	stressed	_	_	_	_
13-5	1637-1641	that	_	_	_	_
13-6	1642-1647	these	abstract[75]	giv[75]	coref	17-37[122_75]
13-7	1648-1657	syndromes	abstract[75]	giv[75]	_	_
13-8	1658-1661	are	_	_	_	_
13-9	1662-1668	caused	_	_	_	_
13-10	1669-1671	by	_	_	_	_
13-11	1672-1681	mutations	abstract[76]	new[76]	_	_
13-12	1682-1684	of	abstract[76]	new[76]	_	_
13-13	1685-1696	cytoplasmic	abstract[76]|substance[77]	new[76]|giv[77]	_	_
13-14	1697-1705	proteins	abstract[76]|substance[77]	new[76]|giv[77]	_	_
13-15	1706-1707	,	_	_	_	_
13-16	1708-1713	which	_	_	_	_
13-17	1714-1717	may	_	_	_	_
13-18	1718-1728	contradict	_	_	_	_
13-19	1729-1732	the	abstract[78]	new[78]	coref	14-6[83_78]
13-20	1733-1743	historical	abstract[78]	new[78]	_	_
13-21	1744-1754	hypothesis	abstract[78]	new[78]	_	_
13-22	1755-1759	that	abstract[78]	new[78]	_	_
13-23	1760-1767	nucleus	abstract[78]|place	new[78]|new	coref	21-31[145_0]
13-24	1768-1770	is	abstract[78]	new[78]	_	_
13-25	1771-1774	the	abstract[78]	new[78]	_	_
13-26	1775-1779	most	abstract[78]	new[78]	_	_
13-27	1780-1794	radiosensitive	abstract[78]	new[78]	_	_
13-28	1795-1799	part	abstract[78]	new[78]	_	_
13-29	1800-1802	of	abstract[78]	new[78]	_	_
13-30	1803-1806	the	abstract[78]|abstract[80]	new[78]|new[80]	_	_
13-31	1807-1811	cell	abstract[78]|abstract[80]	new[78]|new[80]	_	_
13-32	1812-1813	(	_	_	_	_
13-33	1814-1817	see	_	_	_	_
13-34	1818-1821	the	abstract[81]	new[81]	ana	14-3[0_81]
13-35	1822-1834	Introduction	abstract[81]	new[81]	_	_
13-36	1835-1836	)	_	_	_	_
13-37	1837-1838	.	_	_	_	_

#Text=Furthermore , it also contradicts the hypothesis that defect of DSB repair is the unique cause of cellular radiosensitivity .
14-1	1839-1850	Furthermore	_	_	_	_
14-2	1851-1852	,	_	_	_	_
14-3	1853-1855	it	abstract	giv	_	_
14-4	1856-1860	also	_	_	_	_
14-5	1861-1872	contradicts	_	_	_	_
14-6	1873-1876	the	abstract[83]	giv[83]	coref	21-9[140_83]
14-7	1877-1887	hypothesis	abstract[83]	giv[83]	_	_
14-8	1888-1892	that	_	_	_	_
14-9	1893-1899	defect	abstract[84]	giv[84]	coref	14-14[87_84]
14-10	1900-1902	of	abstract[84]	giv[84]	_	_
14-11	1903-1906	DSB	abstract[84]|abstract|abstract[86]	giv[84]|new|new[86]	coref|coref|coref|coref	15-33|15-34[0_86]|15-33|15-34[0_86]
14-12	1907-1913	repair	abstract[84]|abstract[86]	giv[84]|new[86]	_	_
14-13	1914-1916	is	_	_	_	_
14-14	1917-1920	the	abstract[87]	giv[87]	_	_
14-15	1921-1927	unique	abstract[87]	giv[87]	_	_
14-16	1928-1933	cause	abstract[87]	giv[87]	_	_
14-17	1934-1936	of	abstract[87]	giv[87]	_	_
14-18	1937-1945	cellular	abstract[87]|abstract[88]	giv[87]|giv[88]	coref	15-24[95_88]
14-19	1946-1962	radiosensitivity	abstract[87]|abstract[88]	giv[87]|giv[88]	_	_
14-20	1963-1964	.	_	_	_	_

#Text=The question of how to build a unified model that would describe both hyper-radiosensitivity observed in LIG4 - and ATM -mutated cells and moderate radiosensitivity caused by impairment of alternative signaling and DSB repair pathways remains .
15-1	1965-1968	The	abstract[89]	new[89]	_	_
15-2	1969-1977	question	abstract[89]	new[89]	_	_
15-3	1978-1980	of	abstract[89]	new[89]	_	_
15-4	1981-1984	how	abstract[89]	new[89]	_	_
15-5	1985-1987	to	_	_	_	_
15-6	1988-1993	build	_	_	_	_
15-7	1994-1995	a	abstract[90]	new[90]	coref	20-33[133_90]
15-8	1996-2003	unified	abstract[90]	new[90]	_	_
15-9	2004-2009	model	abstract[90]	new[90]	_	_
15-10	2010-2014	that	_	_	_	_
15-11	2015-2020	would	_	_	_	_
15-12	2021-2029	describe	_	_	_	_
15-13	2030-2034	both	abstract[91]	new[91]	coref	34-37[0_91]
15-14	2035-2057	hyper-radiosensitivity	abstract[91]	new[91]	_	_
15-15	2058-2066	observed	_	_	_	_
15-16	2067-2069	in	_	_	_	_
15-17	2070-2074	LIG4	abstract	giv	coref	34-30
15-18	2075-2076	-	_	_	_	_
15-19	2077-2080	and	_	_	_	_
15-20	2081-2084	ATM	object	giv	coref	16-5
15-21	2085-2093	-mutated	object[94]	giv[94]	coref	25-5[166_94]
15-22	2094-2099	cells	object[94]	giv[94]	_	_
15-23	2100-2103	and	object[94]	giv[94]	_	_
15-24	2104-2112	moderate	object[94]|abstract[95]	giv[94]|giv[95]	coref	20-24[0_95]
15-25	2113-2129	radiosensitivity	object[94]|abstract[95]	giv[94]|giv[95]	_	_
15-26	2130-2136	caused	_	_	_	_
15-27	2137-2139	by	_	_	_	_
15-28	2140-2150	impairment	abstract[96]	new[96]	_	_
15-29	2151-2153	of	abstract[96]	new[96]	_	_
15-30	2154-2165	alternative	abstract[96]|abstract[97]	new[96]|new[97]	_	_
15-31	2166-2175	signaling	abstract[96]|abstract[97]	new[96]|new[97]	_	_
15-32	2176-2179	and	abstract[96]	new[96]	_	_
15-33	2180-2183	DSB	abstract[96]|abstract|abstract[100]	new[96]|giv|new[100]	coref|coref	16-16|16-16
15-34	2184-2190	repair	abstract[96]|abstract|abstract[100]	new[96]|giv|new[100]	coref	17-12
15-35	2191-2199	pathways	abstract[96]|abstract[100]	new[96]|new[100]	_	_
15-36	2200-2207	remains	_	_	_	_
15-37	2208-2209	.	_	_	_	_

#Text=To date , the ATM protein has been considered as an early actor of the DSB recognition via its phosphorylation of H2AX and the individual radiation response .
16-1	2210-2212	To	_	_	_	_
16-2	2213-2217	date	time	new	_	_
16-3	2218-2219	,	_	_	_	_
16-4	2220-2223	the	substance[103]	new[103]	ana	16-19[0_103]
16-5	2224-2227	ATM	object|substance[103]	giv|new[103]	coref	17-3
16-6	2228-2235	protein	substance[103]	new[103]	_	_
16-7	2236-2239	has	_	_	_	_
16-8	2240-2244	been	_	_	_	_
16-9	2245-2255	considered	_	_	_	_
16-10	2256-2258	as	_	_	_	_
16-11	2259-2261	an	_	_	_	_
16-12	2262-2267	early	_	_	_	_
16-13	2268-2273	actor	_	_	_	_
16-14	2274-2276	of	_	_	_	_
16-15	2277-2280	the	abstract[105]	new[105]	_	_
16-16	2281-2284	DSB	abstract|abstract[105]	giv|new[105]	coref	17-11
16-17	2285-2296	recognition	abstract[105]	new[105]	_	_
16-18	2297-2300	via	abstract[105]	new[105]	_	_
16-19	2301-2304	its	abstract[105]|substance|abstract[107]	new[105]|giv|new[107]	coref|coref	20-10[128_0]|20-10[128_0]
16-20	2305-2320	phosphorylation	abstract[105]|abstract[107]	new[105]|new[107]	_	_
16-21	2321-2323	of	abstract[105]|abstract[107]	new[105]|new[107]	_	_
16-22	2324-2328	H2AX	abstract[105]|abstract[107]|abstract	new[105]|new[107]|new	coref	22-9
16-23	2329-2332	and	abstract[105]	new[105]	_	_
16-24	2333-2336	the	abstract[105]|abstract[110]	new[105]|new[110]	coref	20-41[136_110]
16-25	2337-2347	individual	abstract[105]|abstract[110]	new[105]|new[110]	_	_
16-26	2348-2357	radiation	abstract[105]|abstract|abstract[110]	new[105]|new|new[110]	coref	20-43
16-27	2358-2366	response	abstract[105]|abstract[110]	new[105]|new[110]	_	_
16-28	2367-2368	.	_	_	_	_

#Text=Surprisingly , ATM has not been integrated in all the DSB repair models discussed above while mutations of RAD51 and RAD52 ( for HR ) and Ku and DNA-PKcs ( for NHEJ ) do not cause any viable syndromes in humans (
17-1	2369-2381	Surprisingly	_	_	_	_
17-2	2382-2383	,	_	_	_	_
17-3	2384-2387	ATM	object	giv	coref	20-10
17-4	2388-2391	has	_	_	_	_
17-5	2392-2395	not	_	_	_	_
17-6	2396-2400	been	_	_	_	_
17-7	2401-2411	integrated	_	_	_	_
17-8	2412-2414	in	_	_	_	_
17-9	2415-2418	all	abstract[114]	giv[114]	coref	35-26[236_114]
17-10	2419-2422	the	abstract[114]	giv[114]	_	_
17-11	2423-2426	DSB	abstract|abstract[114]	giv|giv[114]	coref	22-12
17-12	2427-2433	repair	abstract|abstract[114]	giv|giv[114]	coref	23-9
17-13	2434-2440	models	abstract[114]	giv[114]	_	_
17-14	2441-2450	discussed	_	_	_	_
17-15	2451-2456	above	_	_	_	_
17-16	2457-2462	while	_	_	_	_
17-17	2463-2472	mutations	abstract[115]	new[115]	_	_
17-18	2473-2475	of	abstract[115]	new[115]	_	_
17-19	2476-2481	RAD51	abstract[115]|abstract	new[115]|new	_	_
17-20	2482-2485	and	abstract[115]	new[115]	_	_
17-21	2486-2491	RAD52	abstract[115]|abstract[117]	new[115]|new[117]	_	_
17-22	2492-2493	(	abstract[115]|abstract[117]	new[115]|new[117]	_	_
17-23	2494-2497	for	abstract[115]|abstract[117]	new[115]|new[117]	_	_
17-24	2498-2500	HR	abstract[115]|abstract[117]|abstract	new[115]|new[117]|new	_	_
17-25	2501-2502	)	abstract[115]|abstract[117]	new[115]|new[117]	_	_
17-26	2503-2506	and	_	_	_	_
17-27	2507-2509	Ku	abstract	new	_	_
17-28	2510-2513	and	_	_	_	_
17-29	2514-2522	DNA-PKcs	abstract[120]	giv[120]	_	_
17-30	2523-2524	(	abstract[120]	giv[120]	_	_
17-31	2525-2528	for	abstract[120]	giv[120]	_	_
17-32	2529-2533	NHEJ	abstract[120]|abstract	giv[120]|giv	coref	22-17
17-33	2534-2535	)	abstract[120]	giv[120]	_	_
17-34	2536-2538	do	_	_	_	_
17-35	2539-2542	not	_	_	_	_
17-36	2543-2548	cause	_	_	_	_
17-37	2549-2552	any	abstract[122]	giv[122]	coref	35-10[0_122]
17-38	2553-2559	viable	abstract[122]	giv[122]	_	_
17-39	2560-2569	syndromes	abstract[122]	giv[122]	_	_
17-40	2570-2572	in	abstract[122]	giv[122]	_	_
17-41	2573-2579	humans	abstract[122]|person	giv[122]|new	_	_
17-42	2580-2581	(	_	_	_	_

#Text=Figure 1
18-1	2582-2588	Figure	object[124]	new[124]	_	_
18-2	2589-2590	1	object[124]	new[124]	_	_

#Text=) .
19-1	2591-2592	)	_	_	_	_
19-2	2593-2594	.	_	_	_	_

#Text=Recently , the delay in the radiation-induced nucleo-shuttling of ATM protein ( RIANS ) was shown to be a reliable parameter for predicting radiosensitivity and to provide a biologically relevant interpretation of the linear-quadratic model , the mathematical basis of the cellular radiation response .
20-1	2595-2603	Recently	_	_	_	_
20-2	2604-2605	,	_	_	_	_
20-3	2606-2609	the	abstract[125]	new[125]	coref	32-22[202_125]
20-4	2610-2615	delay	abstract[125]	new[125]	_	_
20-5	2616-2618	in	abstract[125]	new[125]	_	_
20-6	2619-2622	the	abstract[125]|substance[126]	new[125]|new[126]	_	_
20-7	2623-2640	radiation-induced	abstract[125]|substance[126]	new[125]|new[126]	_	_
20-8	2641-2657	nucleo-shuttling	abstract[125]|substance[126]	new[125]|new[126]	_	_
20-9	2658-2660	of	abstract[125]|substance[126]	new[125]|new[126]	_	_
20-10	2661-2664	ATM	abstract[125]|substance[126]|object|substance[128]	new[125]|new[126]|giv|giv[128]	coref|coref	21-25|21-25
20-11	2665-2672	protein	abstract[125]|substance[126]|substance[128]	new[125]|new[126]|giv[128]	_	_
20-12	2673-2674	(	_	_	_	_
20-13	2675-2680	RIANS	abstract	new	coref	21-6
20-14	2681-2682	)	_	_	_	_
20-15	2683-2686	was	_	_	_	_
20-16	2687-2692	shown	_	_	_	_
20-17	2693-2695	to	_	_	_	_
20-18	2696-2698	be	_	_	_	_
20-19	2699-2700	a	abstract[130]	new[130]	_	_
20-20	2701-2709	reliable	abstract[130]	new[130]	_	_
20-21	2710-2719	parameter	abstract[130]	new[130]	_	_
20-22	2720-2723	for	_	_	_	_
20-23	2724-2734	predicting	_	_	_	_
20-24	2735-2751	radiosensitivity	abstract	giv	coref	25-7[167_0]
20-25	2752-2755	and	_	_	_	_
20-26	2756-2758	to	_	_	_	_
20-27	2759-2766	provide	_	_	_	_
20-28	2767-2768	a	abstract[132]	new[132]	_	_
20-29	2769-2781	biologically	abstract[132]	new[132]	_	_
20-30	2782-2790	relevant	abstract[132]	new[132]	_	_
20-31	2791-2805	interpretation	abstract[132]	new[132]	_	_
20-32	2806-2808	of	abstract[132]	new[132]	_	_
20-33	2809-2812	the	abstract[132]|abstract[133]	new[132]|giv[133]	appos	20-37[134_133]
20-34	2813-2829	linear-quadratic	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
20-35	2830-2835	model	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
20-36	2836-2837	,	_	_	_	_
20-37	2838-2841	the	abstract[134]	giv[134]	coref	21-5[139_134]
20-38	2842-2854	mathematical	abstract[134]	giv[134]	_	_
20-39	2855-2860	basis	abstract[134]	giv[134]	_	_
20-40	2861-2863	of	abstract[134]	giv[134]	_	_
20-41	2864-2867	the	abstract[134]|abstract[136]	giv[134]|giv[136]	coref	35-44[241_136]
20-42	2868-2876	cellular	abstract[134]|abstract[136]	giv[134]|giv[136]	_	_
20-43	2877-2886	radiation	abstract[134]|abstract|abstract[136]	giv[134]|giv|giv[136]	_	_
20-44	2887-2895	response	abstract[134]|abstract[136]	giv[134]|giv[136]	_	_
20-45	2896-2897	.	_	_	_	_

#Text=In the context of the RIANS model , the following mechanistic hypothesis has been proposed : after irradiation , cytoplasmic trans-auto-phosphorylated dimeric forms of ATM become monomeric and diffuse to the nucleus .
21-1	2898-2900	In	_	_	_	_
21-2	2901-2904	the	abstract[137]	new[137]	_	_
21-3	2905-2912	context	abstract[137]	new[137]	_	_
21-4	2913-2915	of	abstract[137]	new[137]	_	_
21-5	2916-2919	the	abstract[137]|abstract[139]	new[137]|giv[139]	coref	35-18[235_139]
21-6	2920-2925	RIANS	abstract[137]|abstract|abstract[139]	new[137]|giv|giv[139]	coref	25-15[170_0]
21-7	2926-2931	model	abstract[137]|abstract[139]	new[137]|giv[139]	_	_
21-8	2932-2933	,	_	_	_	_
21-9	2934-2937	the	abstract[140]	giv[140]	_	_
21-10	2938-2947	following	abstract[140]	giv[140]	_	_
21-11	2948-2959	mechanistic	abstract[140]	giv[140]	_	_
21-12	2960-2970	hypothesis	abstract[140]	giv[140]	_	_
21-13	2971-2974	has	_	_	_	_
21-14	2975-2979	been	_	_	_	_
21-15	2980-2988	proposed	_	_	_	_
21-16	2989-2990	:	_	_	_	_
21-17	2991-2996	after	_	_	_	_
21-18	2997-3008	irradiation	abstract	giv	_	_
21-19	3009-3010	,	_	_	_	_
21-20	3011-3022	cytoplasmic	abstract[143]	new[143]	coref	36-16[246_143]
21-21	3023-3048	trans-auto-phosphorylated	abstract[143]	new[143]	_	_
21-22	3049-3056	dimeric	person|abstract[143]	new|new[143]	_	_
21-23	3057-3062	forms	abstract[143]	new[143]	_	_
21-24	3063-3065	of	abstract[143]	new[143]	_	_
21-25	3066-3069	ATM	abstract[143]|object	new[143]|giv	coref	22-6
21-26	3070-3076	become	_	_	_	_
21-27	3077-3086	monomeric	_	_	_	_
21-28	3087-3090	and	_	_	_	_
21-29	3091-3098	diffuse	_	_	_	_
21-30	3099-3101	to	_	_	_	_
21-31	3102-3105	the	place[145]	giv[145]	coref	24-1[158_145]
21-32	3106-3113	nucleus	place[145]	giv[145]	_	_
21-33	3114-3115	.	_	_	_	_

#Text=In the nucleus , active ATM monomers phosphorylate H2AX molecules at DSB sites , which activates NHEJ .
22-1	3116-3118	In	_	_	_	_
22-2	3119-3122	the	_	_	_	_
22-3	3123-3130	nucleus	_	_	_	_
22-4	3131-3132	,	_	_	_	_
22-5	3133-3139	active	person[147]	new[147]	coref	23-1[154_147]
22-6	3140-3143	ATM	object|person[147]	giv|new[147]	coref	23-2
22-7	3144-3152	monomers	person[147]	new[147]	_	_
22-8	3153-3166	phosphorylate	_	_	_	_
22-9	3167-3171	H2AX	substance|substance[149]	giv|new[149]	_	_
22-10	3172-3181	molecules	substance[149]	new[149]	_	_
22-11	3182-3184	at	substance[149]	new[149]	_	_
22-12	3185-3188	DSB	substance[149]|abstract|place[151]	new[149]|giv|new[151]	coref|coref	23-8|23-8
22-13	3189-3194	sites	substance[149]|place[151]	new[149]|new[151]	_	_
22-14	3195-3196	,	_	_	_	_
22-15	3197-3202	which	_	_	_	_
22-16	3203-3212	activates	_	_	_	_
22-17	3213-3217	NHEJ	abstract	giv	_	_
22-18	3218-3219	.	_	_	_	_

#Text=The ATM monomers will re-dimerize during the DSB repair process .
23-1	3220-3223	The	person[154]	giv[154]	_	_
23-2	3224-3227	ATM	object|person[154]	giv|giv[154]	coref	24-5
23-3	3228-3236	monomers	person[154]	giv[154]	_	_
23-4	3237-3241	will	_	_	_	_
23-5	3242-3253	re-dimerize	_	_	_	_
23-6	3254-3260	during	_	_	_	_
23-7	3261-3264	the	abstract[157]	new[157]	_	_
23-8	3265-3268	DSB	abstract|abstract[157]	giv|new[157]	coref	34-24
23-9	3269-3275	repair	abstract|abstract[157]	giv|new[157]	coref	34-25
23-10	3276-3283	process	abstract[157]	new[157]	_	_
23-11	3284-3285	.	_	_	_	_

#Text=Once in nucleus , ATM may also inhibit MRE11 nuclease activity or any other actor responsible for genomic instability .
24-1	3286-3290	Once	place[158]	giv[158]	_	_
24-2	3291-3293	in	place[158]	giv[158]	_	_
24-3	3294-3301	nucleus	place[158]	giv[158]	_	_
24-4	3302-3303	,	_	_	_	_
24-5	3304-3307	ATM	object	giv	coref	25-11
24-6	3308-3311	may	_	_	_	_
24-7	3312-3316	also	_	_	_	_
24-8	3317-3324	inhibit	_	_	_	_
24-9	3325-3330	MRE11	abstract|abstract[162]	new|new[162]	_	_
24-10	3331-3339	nuclease	event|abstract[162]	new|new[162]	_	_
24-11	3340-3348	activity	abstract[162]	new[162]	_	_
24-12	3349-3351	or	_	_	_	_
24-13	3352-3355	any	person[163]	new[163]	_	_
24-14	3356-3361	other	person[163]	new[163]	_	_
24-15	3362-3367	actor	person[163]	new[163]	_	_
24-16	3368-3379	responsible	person[163]	new[163]	_	_
24-17	3380-3383	for	_	_	_	_
24-18	3384-3391	genomic	abstract[164]	new[164]	_	_
24-19	3392-3403	instability	abstract[164]	new[164]	_	_
24-20	3404-3405	.	_	_	_	_

#Text=By contrast , in cells with moderate radiosensitivity , over-expressed ATM substrates may delay the RIANS , thereby favoring cancer proneness and aging .
25-1	3406-3408	By	_	_	_	_
25-2	3409-3417	contrast	abstract	giv	_	_
25-3	3418-3419	,	_	_	_	_
25-4	3420-3422	in	_	_	_	_
25-5	3423-3428	cells	object[166]	giv[166]	_	_
25-6	3429-3433	with	object[166]	giv[166]	_	_
25-7	3434-3442	moderate	object[166]|abstract[167]	giv[166]|giv[167]	coref	30-4[0_167]
25-8	3443-3459	radiosensitivity	object[166]|abstract[167]	giv[166]|giv[167]	_	_
25-9	3460-3461	,	_	_	_	_
25-10	3462-3476	over-expressed	substance[169]	new[169]	coref	32-34[206_169]
25-11	3477-3480	ATM	object|substance[169]	giv|new[169]	coref	32-32[205_0]
25-12	3481-3491	substrates	substance[169]	new[169]	_	_
25-13	3492-3495	may	_	_	_	_
25-14	3496-3501	delay	_	_	_	_
25-15	3502-3505	the	abstract[170]	giv[170]	coref	31-21[190_170]
25-16	3506-3511	RIANS	abstract[170]	giv[170]	_	_
25-17	3512-3513	,	_	_	_	_
25-18	3514-3521	thereby	_	_	_	_
25-19	3522-3530	favoring	_	_	_	_
25-20	3531-3537	cancer	abstract|abstract[172]|abstract[173]	giv|giv[172]|new[173]	coref|coref|coref|coref|coref|coref|coref|coref|coref	31-37|34-40[225_172]|34-40[226_173]|31-37|34-40[225_172]|34-40[226_173]|31-37|34-40[225_172]|34-40[226_173]
25-21	3538-3547	proneness	abstract[172]|abstract[173]	giv[172]|new[173]	_	_
25-22	3548-3551	and	abstract[173]	new[173]	_	_
25-23	3552-3557	aging	abstract[173]|abstract	new[173]|new	ana	26-1
25-24	3558-3559	.	_	_	_	_

#Text=This is notably the case for huntingtin , neurofibromin , and tuberin .
26-1	3560-3564	This	abstract	giv	coref	26-3[176_0]
26-2	3565-3567	is	_	_	_	_
26-3	3568-3575	notably	abstract[176]	giv[176]	coref	34-45[227_176]
26-4	3576-3579	the	abstract[176]	giv[176]	_	_
26-5	3580-3584	case	abstract[176]	giv[176]	_	_
26-6	3585-3588	for	abstract[176]	giv[176]	_	_
26-7	3589-3599	huntingtin	abstract[176]|substance	giv[176]|new	_	_
26-8	3600-3601	,	abstract[176]	giv[176]	_	_
26-9	3602-3615	neurofibromin	abstract[176]|substance	giv[176]|new	_	_
26-10	3616-3617	,	abstract[176]	giv[176]	_	_
26-11	3618-3621	and	abstract[176]	giv[176]	_	_
26-12	3622-3629	tuberin	abstract[176]|object	giv[176]|new	_	_
26-13	3630-3631	.	_	_	_	_

#Text=(
27-1	3632-3633	(	_	_	_	_

#Text=Figure 6
28-1	3634-3640	Figure	object[180]	new[180]	_	_
28-2	3641-3642	6	object[180]	new[180]	_	_

#Text=) .
29-1	3643-3644	)	_	_	_	_
29-2	3645-3646	.	_	_	_	_

#Text=Three groups of radiosensitivity have been defined :
30-1	3647-3652	Three	abstract[181]	new[181]	_	_
30-2	3653-3659	groups	abstract[181]	new[181]	_	_
30-3	3660-3662	of	abstract[181]	new[181]	_	_
30-4	3663-3679	radiosensitivity	abstract[181]|abstract	new[181]|giv	coref	32-18[201_0]
30-5	3680-3684	have	_	_	_	_
30-6	3685-3689	been	_	_	_	_
30-7	3690-3697	defined	_	_	_	_
30-8	3698-3699	:	_	_	_	_

#Text=Group I ( about 75 % to 85 % whole population ) represents the normosensitive ( radioresistant ) patients with a rapid RIANS after 2 Gy , a low risk of post-radiotherapy tissue reaction and of cancer
31-1	3700-3705	Group	organization	new	coref	32-1[196_0]
31-2	3706-3707	I	person	acc	_	_
31-3	3708-3709	(	_	_	_	_
31-4	3710-3715	about	quantity[185]	new[185]	_	_
31-5	3716-3718	75	quantity[185]	new[185]	_	_
31-6	3719-3720	%	quantity[185]	new[185]	_	_
31-7	3721-3723	to	quantity[185]	new[185]	_	_
31-8	3724-3726	85	quantity[185]|quantity[186]	new[185]|new[186]	coref	32-8[198_186]
31-9	3727-3728	%	quantity[185]|quantity[186]	new[185]|new[186]	_	_
31-10	3729-3734	whole	person[187]	new[187]	coref	32-10[199_187]
31-11	3735-3745	population	person[187]	new[187]	_	_
31-12	3746-3747	)	_	_	_	_
31-13	3748-3758	represents	_	_	_	_
31-14	3759-3762	the	abstract[188]	new[188]	_	_
31-15	3763-3777	normosensitive	abstract[188]	new[188]	_	_
31-16	3778-3779	(	person[189]	new[189]	coref	32-14[200_189]
31-17	3780-3794	radioresistant	person[189]	new[189]	_	_
31-18	3795-3796	)	person[189]	new[189]	_	_
31-19	3797-3805	patients	person[189]	new[189]	_	_
31-20	3806-3810	with	person[189]	new[189]	_	_
31-21	3811-3812	a	person[189]|abstract[190]	new[189]|giv[190]	coref	35-19[0_190]
31-22	3813-3818	rapid	person[189]|abstract[190]	new[189]|giv[190]	_	_
31-23	3819-3824	RIANS	person[189]|abstract[190]	new[189]|giv[190]	_	_
31-24	3825-3830	after	person[189]|abstract[190]	new[189]|giv[190]	_	_
31-25	3831-3832	2	person[189]|abstract[190]|time[191]	new[189]|giv[190]|new[191]	_	_
31-26	3833-3835	Gy	person[189]|abstract[190]|time[191]	new[189]|giv[190]|new[191]	_	_
31-27	3836-3837	,	_	_	_	_
31-28	3838-3839	a	abstract[192]	new[192]	_	_
31-29	3840-3843	low	abstract[192]	new[192]	_	_
31-30	3844-3848	risk	abstract[192]	new[192]	_	_
31-31	3849-3851	of	abstract[192]	new[192]	_	_
31-32	3852-3869	post-radiotherapy	abstract[192]|event[194]	new[192]|new[194]	_	_
31-33	3870-3876	tissue	abstract[192]|object|event[194]	new[192]|new|new[194]	_	_
31-34	3877-3885	reaction	abstract[192]|event[194]	new[192]|new[194]	_	_
31-35	3886-3889	and	_	_	_	_
31-36	3890-3892	of	_	_	_	_
31-37	3893-3899	cancer	event	giv	coref	33-13

#Text=Group II ( about 5 – 20 % of whole population ) represents the patients who elicit a moderate radiosensitivity with a delay in the RIANS due to the sequestration of ATM by mutated and over-expressed substrates .
32-1	3900-3905	Group	organization[196]	giv[196]	coref	34-1[211_196]
32-2	3906-3908	II	organization[196]	giv[196]	_	_
32-3	3909-3910	(	organization[196]	giv[196]	_	_
32-4	3911-3916	about	organization[196]	giv[196]	_	_
32-5	3917-3918	5	organization[196]	giv[196]	_	_
32-6	3919-3920	–	organization[196]	giv[196]	_	_
32-7	3921-3923	20	organization[196]|quantity	giv[196]|new	_	_
32-8	3924-3925	%	organization[196]|quantity[198]	giv[196]|giv[198]	coref	34-4[212_198]
32-9	3926-3928	of	organization[196]|quantity[198]	giv[196]|giv[198]	_	_
32-10	3929-3934	whole	organization[196]|quantity[198]|person[199]	giv[196]|giv[198]|giv[199]	coref	34-4[213_199]
32-11	3935-3945	population	organization[196]|quantity[198]|person[199]	giv[196]|giv[198]|giv[199]	_	_
32-12	3946-3947	)	organization[196]	giv[196]	_	_
32-13	3948-3958	represents	_	_	_	_
32-14	3959-3962	the	person[200]	giv[200]	coref	33-1[207_200]
32-15	3963-3971	patients	person[200]	giv[200]	_	_
32-16	3972-3975	who	_	_	_	_
32-17	3976-3982	elicit	_	_	_	_
32-18	3983-3984	a	abstract[201]	giv[201]	coref	35-7[230_201]
32-19	3985-3993	moderate	abstract[201]	giv[201]	_	_
32-20	3994-4010	radiosensitivity	abstract[201]	giv[201]	_	_
32-21	4011-4015	with	abstract[201]	giv[201]	_	_
32-22	4016-4017	a	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
32-23	4018-4023	delay	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
32-24	4024-4026	in	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
32-25	4027-4030	the	abstract[201]|abstract[202]|abstract[203]	giv[201]|giv[202]|new[203]	_	_
32-26	4031-4036	RIANS	abstract[201]|abstract[202]|abstract[203]	giv[201]|giv[202]|new[203]	_	_
32-27	4037-4040	due	abstract[201]|abstract[202]|abstract[203]	giv[201]|giv[202]|new[203]	_	_
32-28	4041-4043	to	_	_	_	_
32-29	4044-4047	the	abstract[204]	new[204]	_	_
32-30	4048-4061	sequestration	abstract[204]	new[204]	_	_
32-31	4062-4064	of	abstract[204]	new[204]	_	_
32-32	4065-4068	ATM	abstract[204]|object[205]	new[204]|giv[205]	coref	34-11[0_205]
32-33	4069-4071	by	abstract[204]|object[205]	new[204]|giv[205]	_	_
32-34	4072-4079	mutated	abstract[204]|object[205]|substance[206]	new[204]|giv[205]|giv[206]	_	_
32-35	4080-4083	and	abstract[204]|object[205]|substance[206]	new[204]|giv[205]|giv[206]	_	_
32-36	4084-4098	over-expressed	abstract[204]|object[205]|substance[206]	new[204]|giv[205]|giv[206]	_	_
32-37	4099-4109	substrates	abstract[204]|object[205]|substance[206]	new[204]|giv[205]|giv[206]	_	_
32-38	4110-4111	.	_	_	_	_

#Text=These patients are moderately radiosensitive and may have a high risk of cancer or neurodegeneration .
33-1	4112-4117	These	person[207]	giv[207]	coref	34-10[215_207]
33-2	4118-4126	patients	person[207]	giv[207]	_	_
33-3	4127-4130	are	_	_	_	_
33-4	4131-4141	moderately	_	_	_	_
33-5	4142-4156	radiosensitive	_	_	_	_
33-6	4157-4160	and	_	_	_	_
33-7	4161-4164	may	_	_	_	_
33-8	4165-4169	have	_	_	_	_
33-9	4170-4171	a	abstract[208]	new[208]	_	_
33-10	4172-4176	high	abstract[208]	new[208]	_	_
33-11	4177-4181	risk	abstract[208]	new[208]	_	_
33-12	4182-4184	of	abstract[208]	new[208]	_	_
33-13	4185-4191	cancer	abstract[208]|abstract	new[208]|giv	coref	34-42
33-14	4192-4194	or	abstract[208]	new[208]	_	_
33-15	4195-4212	neurodegeneration	abstract[208]|abstract	new[208]|new	_	_
33-16	4213-4214	.	_	_	_	_

#Text=Group III ( <1 % whole population ) represents the ATM -mutated patients with no functional ATM kinase or those who show strong DSB repair defects ( like the LIG4 -mutated patient described above ) , hyper-radiosensitivity , and either high cancer proneness or severe accelerated aging .
34-1	4215-4220	Group	organization[211]	giv[211]	_	_
34-2	4221-4224	III	organization[211]	giv[211]	_	_
34-3	4225-4226	(	_	_	_	_
34-4	4227-4229	<1	quantity[212]|person[213]	giv[212]|giv[213]	_	_
34-5	4230-4231	%	quantity[212]|person[213]	giv[212]|giv[213]	_	_
34-6	4232-4237	whole	person[213]	giv[213]	_	_
34-7	4238-4248	population	person[213]	giv[213]	_	_
34-8	4249-4250	)	_	_	_	_
34-9	4251-4261	represents	_	_	_	_
34-10	4262-4265	the	person[215]	giv[215]	_	_
34-11	4266-4269	ATM	object|person[215]	giv|giv[215]	coref	34-17
34-12	4270-4278	-mutated	person[215]	giv[215]	_	_
34-13	4279-4287	patients	person[215]	giv[215]	_	_
34-14	4288-4292	with	person[215]	giv[215]	_	_
34-15	4293-4295	no	person[215]|abstract[217]	giv[215]|new[217]	_	_
34-16	4296-4306	functional	person[215]|abstract[217]	giv[215]|new[217]	_	_
34-17	4307-4310	ATM	person[215]|object|abstract[217]	giv[215]|giv|new[217]	coref	35-32
34-18	4311-4317	kinase	person[215]|abstract[217]	giv[215]|new[217]	_	_
34-19	4318-4320	or	person[215]	giv[215]	_	_
34-20	4321-4326	those	person[215]	giv[215]	_	_
34-21	4327-4330	who	_	_	_	_
34-22	4331-4335	show	_	_	_	_
34-23	4336-4342	strong	abstract[220]	new[220]	_	_
34-24	4343-4346	DSB	abstract|abstract[220]	giv|new[220]	coref	36-26
34-25	4347-4353	repair	abstract|abstract[220]	giv|new[220]	coref	36-27
34-26	4354-4361	defects	abstract[220]	new[220]	_	_
34-27	4362-4363	(	abstract[220]	new[220]	_	_
34-28	4364-4368	like	abstract[220]	new[220]	_	_
34-29	4369-4372	the	abstract[220]|person[222]	new[220]|new[222]	_	_
34-30	4373-4377	LIG4	abstract[220]|abstract|person[222]	new[220]|giv|new[222]	_	_
34-31	4378-4386	-mutated	abstract[220]|person[222]	new[220]|new[222]	_	_
34-32	4387-4394	patient	abstract[220]|person[222]	new[220]|new[222]	_	_
34-33	4395-4404	described	abstract[220]	new[220]	_	_
34-34	4405-4410	above	abstract[220]	new[220]	_	_
34-35	4411-4412	)	abstract[220]	new[220]	_	_
34-36	4413-4414	,	abstract[220]	new[220]	_	_
34-37	4415-4437	hyper-radiosensitivity	abstract[220]|abstract	new[220]|giv	_	_
34-38	4438-4439	,	abstract[220]	new[220]	_	_
34-39	4440-4443	and	abstract[220]	new[220]	_	_
34-40	4444-4450	either	abstract[220]|abstract[225]|abstract[226]	new[220]|giv[225]|giv[226]	_	_
34-41	4451-4455	high	abstract[220]|abstract[225]|abstract[226]	new[220]|giv[225]|giv[226]	_	_
34-42	4456-4462	cancer	abstract[220]|abstract|abstract[225]|abstract[226]	new[220]|giv|giv[225]|giv[226]	_	_
34-43	4463-4472	proneness	abstract[220]|abstract[225]|abstract[226]	new[220]|giv[225]|giv[226]	_	_
34-44	4473-4475	or	abstract[220]|abstract[226]	new[220]|giv[226]	_	_
34-45	4476-4482	severe	abstract[220]|abstract[226]|abstract[227]	new[220]|giv[226]|giv[227]	ana	35-2[0_227]
34-46	4483-4494	accelerated	abstract[220]|abstract[226]|abstract[227]	new[220]|giv[226]|giv[227]	_	_
34-47	4495-4500	aging	abstract[220]|abstract[226]|abstract[227]	new[220]|giv[226]|giv[227]	_	_
34-48	4501-4502	.	_	_	_	_

#Text=While it provides relevant explanation of the radiosensitivity of syndromes caused by mutations of cytoplasmic proteins , the RIANS model appears to be compatible with all the alternative models , as ATM is upstream of all the cascades of radiation-induced phosphorylations involved in the individual response to IR .
35-1	4503-4508	While	_	_	_	_
35-2	4509-4511	it	abstract	giv	_	_
35-3	4512-4520	provides	_	_	_	_
35-4	4521-4529	relevant	abstract[229]	new[229]	_	_
35-5	4530-4541	explanation	abstract[229]	new[229]	_	_
35-6	4542-4544	of	abstract[229]	new[229]	_	_
35-7	4545-4548	the	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
35-8	4549-4565	radiosensitivity	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
35-9	4566-4568	of	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
35-10	4569-4578	syndromes	abstract[229]|abstract[230]|abstract	new[229]|giv[230]|giv	_	_
35-11	4579-4585	caused	_	_	_	_
35-12	4586-4588	by	_	_	_	_
35-13	4589-4598	mutations	abstract[232]	new[232]	_	_
35-14	4599-4601	of	abstract[232]	new[232]	_	_
35-15	4602-4613	cytoplasmic	abstract[232]|object[233]	new[232]|new[233]	_	_
35-16	4614-4622	proteins	abstract[232]|object[233]	new[232]|new[233]	_	_
35-17	4623-4624	,	_	_	_	_
35-18	4625-4628	the	abstract[235]	giv[235]	_	_
35-19	4629-4634	RIANS	object|abstract[235]	giv|giv[235]	_	_
35-20	4635-4640	model	abstract[235]	giv[235]	_	_
35-21	4641-4648	appears	_	_	_	_
35-22	4649-4651	to	_	_	_	_
35-23	4652-4654	be	_	_	_	_
35-24	4655-4665	compatible	_	_	_	_
35-25	4666-4670	with	_	_	_	_
35-26	4671-4674	all	abstract[236]	giv[236]	_	_
35-27	4675-4678	the	abstract[236]	giv[236]	_	_
35-28	4679-4690	alternative	abstract[236]	giv[236]	_	_
35-29	4691-4697	models	abstract[236]	giv[236]	_	_
35-30	4698-4699	,	_	_	_	_
35-31	4700-4702	as	_	_	_	_
35-32	4703-4706	ATM	place	giv	coref	35-34[238_0]
35-33	4707-4709	is	_	_	_	_
35-34	4710-4718	upstream	place[238]	giv[238]	coref	36-17[0_238]
35-35	4719-4721	of	place[238]	giv[238]	_	_
35-36	4722-4725	all	place[238]|abstract[239]	giv[238]|new[239]	_	_
35-37	4726-4729	the	place[238]|abstract[239]	giv[238]|new[239]	_	_
35-38	4730-4738	cascades	place[238]|abstract[239]	giv[238]|new[239]	_	_
35-39	4739-4741	of	place[238]|abstract[239]	giv[238]|new[239]	_	_
35-40	4742-4759	radiation-induced	place[238]|abstract[239]|abstract[240]	giv[238]|new[239]|new[240]	_	_
35-41	4760-4776	phosphorylations	place[238]|abstract[239]|abstract[240]	giv[238]|new[239]|new[240]	_	_
35-42	4777-4785	involved	_	_	_	_
35-43	4786-4788	in	_	_	_	_
35-44	4789-4792	the	abstract[241]	giv[241]	_	_
35-45	4793-4803	individual	abstract[241]	giv[241]	_	_
35-46	4804-4812	response	abstract[241]	giv[241]	_	_
35-47	4813-4815	to	abstract[241]	giv[241]	_	_
35-48	4816-4818	IR	abstract[241]|abstract	giv[241]|new	_	_
35-49	4819-4820	.	_	_	_	_

#Text=Obviously , further investigations are needed to better understand the direct or indirect role of cytoplasmic ATM forms in the activation or the inhibition of DSB repair pathways .
36-1	4821-4830	Obviously	_	_	_	_
36-2	4831-4832	,	_	_	_	_
36-3	4833-4840	further	abstract[243]	new[243]	_	_
36-4	4841-4855	investigations	abstract[243]	new[243]	_	_
36-5	4856-4859	are	_	_	_	_
36-6	4860-4866	needed	_	_	_	_
36-7	4867-4869	to	_	_	_	_
36-8	4870-4876	better	_	_	_	_
36-9	4877-4887	understand	_	_	_	_
36-10	4888-4891	the	abstract[244]	new[244]	_	_
36-11	4892-4898	direct	abstract[244]	new[244]	_	_
36-12	4899-4901	or	abstract[244]	new[244]	_	_
36-13	4902-4910	indirect	abstract[244]	new[244]	_	_
36-14	4911-4915	role	abstract[244]	new[244]	_	_
36-15	4916-4918	of	abstract[244]	new[244]	_	_
36-16	4919-4930	cytoplasmic	abstract[244]|abstract[246]	new[244]|giv[246]	_	_
36-17	4931-4934	ATM	abstract[244]|object|abstract[246]	new[244]|giv|giv[246]	_	_
36-18	4935-4940	forms	abstract[244]|abstract[246]	new[244]|giv[246]	_	_
36-19	4941-4943	in	abstract[244]|abstract[246]	new[244]|giv[246]	_	_
36-20	4944-4947	the	abstract[244]|abstract[246]|event[247]	new[244]|giv[246]|new[247]	_	_
36-21	4948-4958	activation	abstract[244]|abstract[246]|event[247]	new[244]|giv[246]|new[247]	_	_
36-22	4959-4961	or	abstract[244]|abstract[246]	new[244]|giv[246]	_	_
36-23	4962-4965	the	abstract[244]|abstract[246]|event[248]	new[244]|giv[246]|new[248]	_	_
36-24	4966-4976	inhibition	abstract[244]|abstract[246]|event[248]	new[244]|giv[246]|new[248]	_	_
36-25	4977-4979	of	abstract[244]|abstract[246]|event[248]	new[244]|giv[246]|new[248]	_	_
36-26	4980-4983	DSB	abstract[244]|abstract[246]|event[248]|abstract|abstract[251]	new[244]|giv[246]|new[248]|giv|new[251]	_	_
36-27	4984-4990	repair	abstract[244]|abstract[246]|event[248]|abstract|abstract[251]	new[244]|giv[246]|new[248]|giv|new[251]	_	_
36-28	4991-4999	pathways	abstract[244]|abstract[246]|event[248]|abstract[251]	new[244]|giv[246]|new[248]|new[251]	_	_
36-29	5000-5001	.	_	_	_	_
